EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Daniel R Carrizosa iD, Michael Rothe, Pam K Mangat iD, Elizabeth Garrett-Mayer iD, Deepti Behl iD, Bamidele Adesunloye, Evan Pisick, Kathleen W Beekman iD, Efrat Dotan iD, Mehmet Akce iD, Olatunji B Alese iD, Vaibhav Sahai iD und 19 weitere

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00716 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Daniel R Carrizosa und 30 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Ataxia Telangiectasia Mutated Proteins, Neoplasms. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of four cohorts of patients with ATM -altered tumors treated with olaparib are reported: colorectal cancer (CRC), lung cancer (LC), pancreatic cancer (PC), and other solid tumors (histology-pooled, HP). METHODS Eligible patients had advanced solid tumors, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; α = .10). For the HP cohort, the hypothesized null DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points were OR, progression-free survival, overall survival, duration of response or SD, and safety. RESULTS Patients with CRC (n = 30), LC (n = 20), PC (n = 28), or other advanced cancers (n = 38) with ATM alterations were enrolled. The DC rates were 23% (one-sided 90% CI, 8 to 100; P = .38), 45% (one-sided 90% CI, 32 to 100; P = .0004), 28% (one-sided 90% CI, 14 to 100; P = .14), and 25% (one-sided 90% CI, 16 to 100), respectively. The null hypothesized 15% DC rate was rejected for the LC and HP cohorts but not the CRC and PC cohorts. Twenty of 116 patients (17%) experienced treatment-related grade 3 adverse events (AE) or serious AEs. CONCLUSION Olaparib met the prespecified criteria to declare a signal of activity in patients with ATM -altered cancer within the LC and HP cohorts but not the CRC or PC cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPhthalazinesAtaxia Telangiectasia Mutated ProteinsNeoplasmsAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedRegistriesAdultPancreatic NeoplasmsAged, 80 and over

Substanzen

PiperazinesolaparibPhthalazinesAtaxia Telangiectasia Mutated ProteinsATM protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Sutter Cancer Research Consortium, Sacramento, CA.
  • City of Hope - Atlanta, Atlanta, GA.
  • City of Hope - Chicago, Zion, IL.
  • Trinity Health IHA Medical Group, Ypsilanti, MI.

ORCID-Profile: Daniel R Carrizosa, Pam K Mangat, Elizabeth Garrett-Mayer, Deepti Behl, Kathleen W Beekman, Efrat Dotan, Mehmet Akce, Olatunji B Alese, Vaibhav Sahai, Kelsey A Klute, Jeanny B Aragon-Ching, Ramya Thota, Funda Meric-Bernstam, Peter J Hosein, Justin T Moyers, Steven Powell, Song Zhao, Evthokia Hobbs, Jens Rueter, Davendra P S Sohal, Dominique C Hinshaw, Abigail Gregory, Gina N Grantham, Susan Halabi, Richard L Schilsky

Zitieren

APA

Carrizosa, D. R., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Behl, D., Adesunloye, B., Pisick, E., Beekman, K. W., Dotan, E., Akce, M., Alese, O. B., Sahai, V., Klute, K. A., Aragon-Ching, J. B., Cooper, K. A., Thota, R., Meric-Bernstam, F., Hosein, P. J., Maestas, E. C., …, & Schilsky, R. L. (2026). Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. https://doi.org/10.1200/po-25-00716

Vancouver

Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, et al. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precision Oncology. 2026. doi:10.1200/po-25-00716

BibTeX
@article{Carrizosa2026,
  author = {Carrizosa, Daniel R and Rothe, Michael and Mangat, Pam K and Garrett-Mayer, Elizabeth and Behl, Deepti and Adesunloye, Bamidele and Pisick, Evan and Beekman, Kathleen W and Dotan, Efrat and Akce, Mehmet and Alese, Olatunji B and Sahai, Vaibhav and Klute, Kelsey A and Aragon-Ching, Jeanny B and Cooper, Kathrine A and Thota, Ramya and Meric-Bernstam, Funda and Hosein, Peter J and Maestas, Erika C and Moyers, Justin T and Powell, Steven and Zhao, Song and Hobbs, Evthokia and Rueter, Jens and Sohal, Davendra P S and Taylor, Mark A and Hinshaw, Dominique C and Gregory, Abigail and Grantham, Gina N and Halabi, Susan and Schilsky, Richard L},
  title = {Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00716}
}
Kostenlos starten →